DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.

[1]  L. Nadler,et al.  Correspondence re R. Lapointe et al., CD40-stimulated B Lymphocytes Pulsed with Tumor Antigens Are Effective Antigen-presenting Cells That Can Generate Specific T Cells. Cancer Res 2003;63:2836–43. , 2004, Cancer Research.

[2]  C. Figdor,et al.  Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.

[3]  S. Grupp,et al.  RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. , 2004, Blood.

[4]  M. Tanimoto,et al.  Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. , 2004, Blood.

[5]  Ulrich H. von Andrian,et al.  Homing and cellular traffic in lymph nodes , 2003, Nature Reviews Immunology.

[6]  G. Papanicolaou,et al.  Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. , 2003, Blood.

[7]  R. Zeuner,et al.  Differential signaling by CpG DNA in DCs and B cells: not just TLR9. , 2003, Trends in immunology.

[8]  Antonio Lanzavecchia,et al.  Regulation of Dendritic Cell Migration to the Draining Lymph Node , 2003, The Journal of experimental medicine.

[9]  C. Klein,et al.  Gene therapy to target dendritic cells from blood to lymph nodes , 2003, Gene Therapy.

[10]  R. Steinman,et al.  Activation of Natural Killer T Cells by -Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein , 2003 .

[11]  D. Schadendorf,et al.  Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. , 2003, Blood.

[12]  P. Hwu,et al.  CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. , 2003, Cancer research.

[13]  D. Purdie,et al.  Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine , 2003, Cancer Immunology, Immunotherapy.

[14]  R. Steinman,et al.  The use of dendritic cells in cancer immunotherapy. , 2003, Current opinion in immunology.

[15]  D. Ridgway.  The First 1000 Dendritic Cell Vaccinees , 2003, Cancer investigation.

[16]  Marcela V Maus,et al.  A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. , 2002, Clinical immunology.

[17]  G. Bartsch,et al.  Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  M. Dhodapkar,et al.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Luft,et al.  Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. , 2002, Blood.

[20]  R. Förster,et al.  Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. , 2002, Blood.

[21]  M. Tanimoto,et al.  Efficient Generation of Antigen-Specific Cytotoxic T Cells Using Retrovirally Transduced CD40-Activated B Cells1 , 2002, The Journal of Immunology.

[22]  I. Mellman,et al.  Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Schuler,et al.  Matrix Metalloproteinases 9 and 2 Are Necessary for the Migration of Langerhans Cells and Dermal Dendritic Cells from Human and Murine Skin1 , 2002, The Journal of Immunology.

[24]  K. Anderson,et al.  Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. , 2002, Blood.

[25]  L. Karlsson,et al.  Regulated Expression of Human Histocompatibility Leukocyte Antigen (HLA)-DO During Antigen-dependent and Antigen-independent Phases of B Cell Development , 2002, The Journal of experimental medicine.

[26]  E. Schattner,et al.  Germinal Center B Cells Regulate Their Capability to Present Antigen by Modulation of HLA-DO , 2002, The Journal of experimental medicine.

[27]  D. Czerwinski,et al.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.

[28]  Yong‐jun Liu,et al.  Mouse and human dendritic cell subtypes , 2002, Nature Reviews Immunology.

[29]  Antonio Lanzavecchia,et al.  The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells1 , 2002, The Journal of Immunology.

[30]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[31]  E. Gilboa,et al.  Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. , 2002, The Journal of clinical investigation.

[32]  E. Engleman,et al.  Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy1 , 2001, The Journal of Immunology.

[33]  D. Mann,et al.  Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. , 2001, Clinical immunology.

[34]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[35]  Gerold Schuler,et al.  Dendritic Cells as Vectors for Therapy , 2001, Cell.

[36]  A. Thomson,et al.  Designer dendritic cells for tolerance induction: guided not misguided missiles. , 2001, Trends in immunology.

[37]  A. Enk,et al.  A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection , 2001, International journal of cancer.

[38]  J. Banchereau,et al.  Sensing Pathogens and Tuning Immune Responses , 2001, Science.

[39]  Frank O. Nestle,et al.  Dendritic cells: On the move from bench to bedside , 2001, Nature Medicine.

[40]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[41]  Mark M. Davis,et al.  Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Edgar G. Engleman,et al.  Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1 , 2001, The Journal of Immunology.

[43]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.

[44]  I. Mellman,et al.  Large-Scale Culture and Selective Maturation of Human Langerhans Cells from Granulocyte Colony-Stimulating Factor-Mobilized CD34+ Progenitors1 , 2000, The Journal of Immunology.

[45]  Michel Sadelain,et al.  Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells , 2000, Nature Biotechnology.

[46]  R. Steinman,et al.  Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. , 2000, The Journal of clinical investigation.

[47]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[48]  J. Gribben,et al.  Human Non-Germinal Center B Cell Interleukin (IL)-12 Production Is Primarily Regulated by T Cell Signals CD40 Ligand, Interferon γ, and IL-10: Role of B Cells in the Maintenance of  T Cell Responses , 1999, The Journal of experimental medicine.

[49]  W. Heath,et al.  B Cells Directly Tolerize CD8+ T Cells , 1998, The Journal of experimental medicine.

[50]  R. Zinkernagel,et al.  Dendritic Cells Induce Autoimmune Diabetes and Maintain Disease via De Novo Formation of Local Lymphoid Tissue , 1998, The Journal of experimental medicine.

[51]  E. Butcher,et al.  6-C-kine (SLC), a Lymphocyte Adhesion-triggering Chemokine Expressed by High Endothelium, Is an Agonist for the MIP-3β Receptor CCR7 , 1998, The Journal of cell biology.

[52]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[53]  E. Butcher,et al.  Molecular Mechanisms of Lymphocyte Homing to Peripheral Lymph Nodes , 1998, The Journal of experimental medicine.

[54]  J. Gribben,et al.  CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. , 1997, The Journal of clinical investigation.

[55]  M. Croft,et al.  Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells. , 1997, Journal of immunology.

[56]  M. Croft,et al.  CD40 ligand induction on T cell subsets by peptide-presenting B cells: implications for development of the primary T and B cell response. , 1997, Journal of immunology.

[57]  J. Banchereau,et al.  Functions of CD40 on B cells, dendritic cells and other cells. , 1997, Current opinion in immunology.

[58]  F. Finkelman,et al.  Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. , 1996, Journal of immunology.

[59]  J. West,et al.  B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. , 1995, Journal of immunology.

[60]  J. Banchereau,et al.  Generation of memory B cells and plasma cells in vitro , 1995, Science.

[61]  J. Banchereau,et al.  Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2. , 1995, Immunity.

[62]  C. Janeway,et al.  Do B cells drive the diversification of immune responses? , 1993, Immunology today.

[63]  D. Parker,et al.  Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens , 1992, The Journal of experimental medicine.

[64]  R. Steinman,et al.  Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen , 1975, The Journal of experimental medicine.

[65]  R. Steinman,et al.  IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE , 1973, The Journal of experimental medicine.

[66]  W. Oyen,et al.  Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. , 2003, Cancer research.

[67]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.

[68]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.